32,33,34,35-bacteriohopanetetrol: hopanoid from Rhodopseudomonas acidophila; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
bacteriohopane-32,33,34,35-tetrol : A hopanoid that is bacteriohopane carrying four hydroxy substituents at positions 32, 33, 34 and 35. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 11489675 |
| CHEMBL ID | 442840 |
| CHEBI ID | 132468 |
| SCHEMBL ID | 7896032 |
| MeSH ID | M0154467 |
| Synonym |
|---|
| 32,33,34,35-bacteriohopanetetrol |
| bacteriohopane-32,33,34,35-tetrol |
| bacteriohopanetetrol |
| tetrahydroxybacteriohopane |
| (2s,3s,4r,7r)-7-[(3r,3as,5ar,5br,7as,11as,11br,13ar,13bs)-5a,5b,8,8,11a,13b-hexamethylicosahydro-1h-cyclopenta[a]chrysen-3-yl]octane-1,2,3,4-tetrol |
| (32r,33r,34s)-32,33,34,35-bacteriohopanetetrol |
| CHEBI:132468 |
| CHEMBL442840 |
| 1,2,3,4-octanetetrol, 7-((21alpha)-a'-neo-22,29,30-trinorgammaceran-21-yl)-, (2s-(2r*,3s*,4s*,7s*))- |
| bacteriohopane-tetrol |
| 32,33,34,35-bhtt |
| thbh |
| 51024-98-7 |
| SCHEMBL7896032 |
| C21119 |
| (2s,3r,4r,7r)-7-[(3r,3as,5ar,5br,7as,11as,11br,13ar,13bs)-5a,5b,8,8,11a,13b-hexamethyl-1,2,3,3a,4,5,6,7,7a,9,10,11,11b,12,13,13a-hexadecahydrocyclopenta[a]chrysen-3-yl]octane-1,2,3,4-tetrol |
| DTXSID401046368 |
| Role | Description |
|---|---|
| lipoxygenase inhibitor | A compound or agent that combines with lipoxygenase and thereby prevents its substrate-enzyme combination with arachidonic acid and the formation of the icosanoid products hydroxyicosatetraenoic acid and various leukotrienes. |
| bacterial metabolite | Any prokaryotic metabolite produced during a metabolic reaction in bacteria. |
| antimicrobial agent | A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| hopanoid | A triterpenoid based on a hopane skeleton. |
| tetrol | A polyol that contains 4 hydroxy groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID355220 | Inhibition of soybean 15-lipoxygenase assessed as rate of disappearance of dissolved oxygen at 100 uM relative to control | 1997 | Journal of natural products, Apr, Volume: 60, Issue:4 | Modulation of lipoxygenase activity by bacterial hopanoids. |
| AID355219 | Inhibition of soybean 15-lipoxygenase assessed as rate of disappearance of dissolved oxygen at 50 uM relative to control | 1997 | Journal of natural products, Apr, Volume: 60, Issue:4 | Modulation of lipoxygenase activity by bacterial hopanoids. |
| AID355221 | Inhibition of human recombinant 5-lipoxygenase assessed as rate of disappearance of dissolved oxygen at 25 uM relative to control | 1997 | Journal of natural products, Apr, Volume: 60, Issue:4 | Modulation of lipoxygenase activity by bacterial hopanoids. |
| AID355217 | Inhibition of soybean 15-lipoxygenase assessed as rate of disappearance of dissolved oxygen at 12.5 uM relative to control | 1997 | Journal of natural products, Apr, Volume: 60, Issue:4 | Modulation of lipoxygenase activity by bacterial hopanoids. |
| AID355216 | Inhibition of soybean 15-lipoxygenase assessed as rate of disappearance of dissolved oxygen at 6.75 uM relative to control | 1997 | Journal of natural products, Apr, Volume: 60, Issue:4 | Modulation of lipoxygenase activity by bacterial hopanoids. |
| AID355223 | Inhibition of cyclooxygenase assessed as rate of disappearance of dissolved oxygen at 25 uM relative to control | 1997 | Journal of natural products, Apr, Volume: 60, Issue:4 | Modulation of lipoxygenase activity by bacterial hopanoids. |
| AID355226 | Inhibition of soybean 15-lipoxygenase | 1997 | Journal of natural products, Apr, Volume: 60, Issue:4 | Modulation of lipoxygenase activity by bacterial hopanoids. |
| AID355218 | Inhibition of soybean 15-lipoxygenase assessed as rate of disappearance of dissolved oxygen at 25 uM relative to control | 1997 | Journal of natural products, Apr, Volume: 60, Issue:4 | Modulation of lipoxygenase activity by bacterial hopanoids. |
| AID355224 | Inhibition of cyclooxygenase assessed as rate of disappearance of dissolved oxygen at 50 uM relative to control | 1997 | Journal of natural products, Apr, Volume: 60, Issue:4 | Modulation of lipoxygenase activity by bacterial hopanoids. |
| AID355222 | Inhibition of human recombinant 5-lipoxygenase assessed as rate of disappearance of dissolved oxygen at 50 uM relative to control | 1997 | Journal of natural products, Apr, Volume: 60, Issue:4 | Modulation of lipoxygenase activity by bacterial hopanoids. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (11.76) | 18.7374 |
| 1990's | 4 (23.53) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.06) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 17 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||